NEJM.org
@nejm.org
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.
Follow @ai.nejm.org for medical AI content.
Follow @ai.nejm.org for medical AI content.
📖 Further reading
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
November 22, 2025 at 8:01 PM
📖 Further reading
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
Original Article by M.J. Bolland et al.: Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age nej.md/4g6wlz3
Editorial: Managing Asymptomatic Carotid Stenosis nej.md/482XjG1
November 21, 2025 at 3:38 PM
Editorial: Managing Asymptomatic Carotid Stenosis nej.md/482XjG1
Listen to the latest episode, “Undervalued,” as well as past episodes, and subscribe to the podcast: nej.md/NOS
November 20, 2025 at 8:35 PM
Listen to the latest episode, “Undervalued,” as well as past episodes, and subscribe to the podcast: nej.md/NOS
Hear more from Dr. Clarkson in “If You Break It, They Won't Come,” episode 3.4 of the Not Otherwise Specified podcast, hosted by NEJM National Correspondent Dr. Lisa Rosenbaum: nej.md/4oPRtyl
November 20, 2025 at 8:35 PM
Hear more from Dr. Clarkson in “If You Break It, They Won't Come,” episode 3.4 of the Not Otherwise Specified podcast, hosted by NEJM National Correspondent Dr. Lisa Rosenbaum: nej.md/4oPRtyl
Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) nej.md/43udoTG
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
November 20, 2025 at 2:06 PM
Efficacy and Safety of mRNA Influenza Vaccine (phase 3 trial) nej.md/43udoTG
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Belzutifan for Pheochromocytoma or Paraganglioma (LITESPARK-015 phase 2 trial) nej.md/475bfP9
Subscribe to NEJM for the latest medical research: nej.md/subscribe
Editorial: An Early Look at mRNA Vaccines to Prevent Influenza nej.md/488N2Z3
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
November 19, 2025 at 10:40 PM
Editorial: An Early Look at mRNA Vaccines to Prevent Influenza nej.md/488N2Z3
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d
📖 Further reading in NEJM Evidence:
Original Article: Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine eviden.cc/4o1zx3d